Close

Credit Suisse Downgrades Bristol-Myers Squibb Co. (BMY) to Neutral

August 8, 2016 6:20 AM EDT Send to a Friend
Credit Suisse downgraded Bristol-Myers Squibb Co. (NYSE: BMY) from Outperform to Neutral with a price target of $63.00 following news ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login